<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01181674</url>
  </required_header>
  <id_info>
    <org_study_id>REMIT Pilot</org_study_id>
    <secondary_id>Control # 139433, 143584</secondary_id>
    <secondary_id>10-346</secondary_id>
    <nct_id>NCT01181674</nct_id>
  </id_info>
  <brief_title>Remission Evaluation of Metabolic Interventions in Type 2 Diabetes (REMIT Pilot Trial)</brief_title>
  <official_title>Remission Evaluation of Metabolic Interventions in Type 2 Diabetes (REMIT): A Randomized Controlled Pilot Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Population Health Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hamilton Health Sciences Corporation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Population Health Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this pilot trial is to determine whether an intensive treatment with insulin
      glargine, metformin, acarbose and lifestyle can normalize blood glucose levels in patients
      with recently diagnosed type 2 diabetes mellitus when compared to standard diabetes care.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a pilot trial of 125 patients allocated to either usual care (1/3), 2 months or 4
      months of intensive lifestyle and pharmacotherapy followed by cessation of all drug therapy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of participants achieving normoglycemia in the experimental group 1 compared to the control group</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of participants achieving normoglycemia in the experimental group 2 compared to the control group</measure>
    <time_frame>16 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with normal glucose tolerance</measure>
    <time_frame>20 and 28 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with normal fasting plasma glucose</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fasting plasma glucose from baseline</measure>
    <time_frame>Baseline and 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1C</measure>
    <time_frame>8, 20, 28 and 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in weight from baseline</measure>
    <time_frame>Baseline, 8, 20, 28 and 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of symptomatic hypoglycemic episodes</measure>
    <time_frame>28 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of severe hypoglycemic episodes</measure>
    <time_frame>28 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">83</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Group 1 (short)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 (long)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard care</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>insulin glargine</intervention_name>
    <description>sc injection</description>
    <arm_group_label>Group 1 (short)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>metformin</intervention_name>
    <description>oral administration</description>
    <arm_group_label>Group 1 (short)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>acarbose</intervention_name>
    <description>oral administration</description>
    <arm_group_label>Group 1 (short)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>lifestyle therapy</intervention_name>
    <description>diet and exercise</description>
    <arm_group_label>Group 1 (short)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>insulin glargine</intervention_name>
    <description>sc injection</description>
    <arm_group_label>Group 2 (long)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>metformin</intervention_name>
    <description>oral administration</description>
    <arm_group_label>Group 2 (long)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>acarbose</intervention_name>
    <description>oral administration</description>
    <arm_group_label>Group 2 (long)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>lifestyle therapy</intervention_name>
    <description>diet and exercise</description>
    <arm_group_label>Group 2 (long)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard glycemic care</intervention_name>
    <description>as informed by the current clinical practice guidelines</description>
    <arm_group_label>Standard care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. men and women 30-80 years of age inclusive

          2. type 2 diabetes mellitus diagnosed by a physician within 3 years prior to patient
             enrollment

          3. anti-diabetic drug regimen (either drug or dose of drug) unchanged during 8 weeks
             prior to screening and randomization

          4. HbA1C ≤ 8.5% on no oral hypoglycemic agents or HbA1C ≤ 7.5% on 1 agent or on
             half-maximal doses of 2 agents

          5. body mass index ≥ 23 kg/m2

          6. a negative pregnancy test and an agreement to use a reliable method of birth control
             for the duration of the trial in all females with childbearing potential

          7. ability and willingness to perform self-monitoring of capillary blood glucose (SMBG)

          8. ability and willingness to self-inject insulin

          9. provision of informed consent.

        Exclusion Criteria:

          1. current use of insulin therapy

          2. history of hypoglycemia unawareness, or severe hypoglycemia requiring assistance

          3. renal dysfunction as evidenced by serum creatinine (Cr) ≥ 124 μmol/l

          4. history of lactic acidosis or diabetic ketoacidosis

          5. active liver disease or elevated alanine transferase (ALT) levels ≥ 2.5 times upper
             limit of normal at the time of enrollment

          6. history of inflammatory bowel disease, colonic ulcers, recent or significant bowel
             surgery, or predisposition to bowel obstruction

          7. cardiovascular disease including any of:

               -  systolic blood pressure &gt;180 mmHg or diastolic blood pressure &gt;105 mmHg

               -  peripheral vascular disease

               -  left bundle branch block or third degree AV block

               -  tachyarrhythmias or bradyarrhythmias with uncontrolled ventricular rate

               -  stenotic valvular heart disease

               -  cardiomyopathy

               -  history of heart failure

               -  history of aortic dissection

               -  documented history of angina or coronary artery disease

               -  history of stroke or transient ischemic attack

          8. pulmonary disease with dependence on oxygen

          9. history of any disease requiring intermittent or continuous systemic glucocorticoid
             treatment

         10. history of any major illness with a life expectancy of &lt;3 years

         11. history of injury or any other condition that significantly limits participant's
             ability to achieve moderate levels of physical activity

         12. any history of excessive alcohol intake, acute or chronic

         13. known hypersensitivity to metformin, acarbose, or insulin glargine.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hertzel Gerstein, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Population Health Research Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Natalia Yakubovich, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Population Health Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>McMaster University Medical Centre, Diabetes Care and Research Program</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 3Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 11, 2010</study_first_submitted>
  <study_first_submitted_qc>August 12, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 13, 2010</study_first_posted>
  <last_update_submitted>October 20, 2015</last_update_submitted>
  <last_update_submitted_qc>October 20, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 22, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Population Health Research Institute</investigator_affiliation>
    <investigator_full_name>Dr. Hertzel Gerstein</investigator_full_name>
    <investigator_title>Director, Division of Endocrinology and Metabolism, McMaster University</investigator_title>
  </responsible_party>
  <keyword>Diabetes</keyword>
  <keyword>Insulin</keyword>
  <keyword>Glargine</keyword>
  <keyword>Metformin</keyword>
  <keyword>Acarbose</keyword>
  <keyword>Diet</keyword>
  <keyword>Exercise</keyword>
  <keyword>Lifestyle</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Insulin Glargine</mesh_term>
    <mesh_term>Acarbose</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

